07 December 2023>: Clinical Research
Prognostic Factors for Uterine Sarcoma and Carcinosarcoma: Insights from a 10-Year Follow-Up Study
Beata Kotowicz 1ACDEF* , Anna Dańska-Bidzińska 2ABDEG , Małgorzata Fuksiewicz 1BCDE , Anna Nasierowska-Guttmejer 3BC , Dorota Raczkiewicz 4C , Mariusz Gujski 5BEF , Szymon Piątek 6B , Mariusz Bidziński 6AEGDOI: 10.12659/MSM.941562
Med Sci Monit 2023; 29:e941562
Table 1 Patients’ characteristics.
Variable, parameter | Unit or category | Number of patients (%) (n=52) |
---|---|---|
Age of onset, min-max, median | Years | 56 (23–93) |
Age group | 32 (62) | |
≥60 years | 20 (38) | |
FIGO stage | IA | 11 (21) |
IB | 24 (46) | |
IIA | 12 (23) | |
IIB | 4 (8) | |
IIIA | 1 (2) | |
Type of tumor | Primary | 38 (73) |
Recurrent | 14 (27) | |
Histology type | Carcinosarcoma | 18 (35) |
Leiomyosarcoma | 13 (25) | |
ESS high grade* | 10 (19) | |
Adenosarcoma | 5 (10) | |
ESS low grade* | 4 (8) | |
Rhabdomyosarcoma | 1 (2) | |
Solitary fibrous tumor (malignant) | 1 (2) | |
Type of adjuvant treatment | Chemotherapy | 24 (46) |
Radiotherapy | 8 (16) | |
Hormonal treatment | 9 (17) | |
No treatment | 11 (21) | |
Mitotic index Ki 67 | Low | 12 (23) |
Medium | 8 (15) | |
High | 32 (62) | |
p53 | Low | 11 (21) |
High | 41 (79) | |
Estrogen receptors status | Low | 37 (71) |
High | 15 (29) | |
Progesterone receptors status | Low | 43 (83) |
High | 9 (17) | |
* ESS – endometrial stromal sarcoma. |